Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
about
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsAn Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeNevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virusProtease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeMetabolic effects of indinavir in healthy HIV-seronegative menHIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitusCardiovascular Complications of HIV in Endemic Countries.Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients.Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics studyEffect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.Antiretroviral therapy in the clinicAntiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTCoronary artery disease and human immunodeficiency virus infection.LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Glucose disorders associated with HIV and its drug therapy.Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposalLipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.Chromium Therapy for Insulin Resistance Associated with HIV-DiseaseClinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?Nutrition and HIV infection.Evaluation and management of dyslipidemia in patients with HIV infection.Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.The epidemiology of the oral lesions of HIV infection in the developed world.Association of visceral adiposity with increased intrarenal artery resistive index in HIV-1-infected patients receiving highly active antiretroviral therapy.Association of antiretroviral therapy with fibrinogen levels in HIV-infection.Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsAccelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapyLeptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.Epidemiology and management of antiretroviral-associated cardiovascular disease.
P2860
Q24598812-FCC4218F-BD2A-4806-99F4-2A87D561A4B8Q24791238-17EE69D1-6281-481E-ADA3-CA08F29373D3Q24802369-58438F0D-CF74-45F4-BFD1-1E9E4A03EFC0Q24814179-AD327BFA-EB30-4712-B6D2-5219C95DACF8Q28344599-EDC21E97-F2C5-4C36-BDCE-F997729B4509Q28366603-F1ED3B31-FA0D-4E03-9A9E-5D1447112FA0Q28582686-218082D8-58BF-4F72-BD10-2EE076AC7474Q30244655-A7DCE4FD-FAF7-4777-837B-9E60DFEEA40DQ30480466-A95D6D51-C6FD-4914-901D-AE515A39D277Q31146395-E0D6C40E-2C7C-4F1F-AF80-3DA1A101EE30Q33361587-5690F212-2249-4B0A-B67A-782F00721627Q33608017-34FE6968-A88B-4765-97E4-122286456B43Q33877347-995EA751-31D1-42CC-9183-89C6CB723467Q33927532-09A099D5-1431-48BB-BA0B-AD4E9991279BQ33952995-5B60A93B-F183-4C21-9D1F-D7ECB211B57DQ34012749-768957EC-8DCE-40B6-935D-0B297A54F75DQ34052597-C5865FC5-B820-4A27-B9CE-C751F4DCCF2AQ34058478-C43E327E-BC91-4A0E-95EE-402FE7246244Q34079102-4A1ACA5B-EE63-4640-A99A-D24B1FCD9797Q34092346-3830FA24-6CE6-4823-8383-ACC9946EE57CQ34191314-2FAA94C4-4813-4689-9EB8-29E60FB15565Q34333596-1EA48454-AAB9-4F7C-9916-3F0A057FF6A8Q34367498-CB35E4A2-881F-471A-A938-92676251C390Q34374679-4D8C96EE-348E-4C59-AF52-48806FF378EEQ34390688-BBE11D2C-EAC0-434B-9155-AC9C7E93093FQ34461377-2CF16A1A-3CAC-48B4-852F-3BCEB8CA6424Q34464649-C6E17E2D-973E-44E2-A658-79E502FFB81DQ34564488-E8BC00F4-4A36-4443-8F04-D83E818314B3Q34743413-6D205393-B073-4138-8A9F-FC759086CA51Q34755325-1C12F824-69EA-4C4F-8CB1-F66500A6355AQ34775248-2850605F-0EC5-4D9F-95A2-D5377342180BQ35117283-35EB4F41-9734-4A87-82C3-1566C63C4AFFQ35166181-FB5CC7ED-C6C3-4952-B8BA-9962A6E3851EQ35176441-6CFC66E4-0177-40A6-B778-3E28C016BD09Q35188653-425741D3-D6A2-45F9-816E-AF9939735C94Q35195035-9D2E3590-82B6-459A-91C3-F55CE8BDC9DCQ35206635-1AE4BF8B-07D0-4EFE-930F-AD5CC3B6EF4EQ35208120-6C2E5BC6-A134-4E15-B2C7-B548FD256556Q35239494-A50698F8-592C-4BB0-8D52-CFD2C73BC5F7Q35338096-EFD3FA01-2208-4421-A115-547F00E7ED14
P2860
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@en
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@nl
type
label
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@en
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@nl
prefLabel
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@en
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@nl
P2093
P1433
P1476
Impaired glucose tolerance, be ...... ment with protease inhibitors.
@en
P2093
Schmidt RE
P304
P356
10.1097/00002030-199907090-00001
P407
P577
1999-07-01T00:00:00Z